Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human gene combination and application thereof to preparation of kit for evaluating sensitivity of cervical cancer neoadjuvant chemotherapy drugs

A chemotherapeutic drug and gene combination technology, applied in the biological field, can solve the problems of adverse reactions, poor prognosis, and poor effect of concurrent radiotherapy and chemotherapy, and achieve the effects of delaying treatment time, high prediction accuracy, and great application value.

Active Publication Date: 2020-11-17
武汉凯德维斯医学检验实验室有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because there is currently no method that can predict the sensitivity of neoadjuvant chemotherapy before chemotherapy, the prognosis of many patients who are not sensitive to neoadjuvant chemotherapy is poor. The effect of other treatments such as radiotherapy and concurrent chemoradiotherapy is poor. If there is no improvement, the economic burden of patients will be increased, and adverse reactions after chemotherapy will be brought

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human gene combination and application thereof to preparation of kit for evaluating sensitivity of cervical cancer neoadjuvant chemotherapy drugs
  • Human gene combination and application thereof to preparation of kit for evaluating sensitivity of cervical cancer neoadjuvant chemotherapy drugs
  • Human gene combination and application thereof to preparation of kit for evaluating sensitivity of cervical cancer neoadjuvant chemotherapy drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Access to human gene panels associated with sensitivity to neoadjuvant chemotherapy drugs in cervical cancer:

[0015] 1. Detection of gene mutations by whole exome sequencing

[0016] Whole-exome sequencing (WES) is used to analyze the DNA of tissue samples from cervical cancer patients with known outcomes of neoadjuvant chemotherapy. Exome sequencing refers to the use of sequence capture or targeted Genome analysis by high-throughput sequencing was performed after enrichment.

[0017] 2. Mutation detection and screening

[0018] Compare the clean data to the human reference genome (B37), use the muTect and Strelka tools to detect somatic SNVs and INDEL, and use the Annovar tool to annotate the gene structure and database. Filter out mutation sites with a minimum allele frequency (MAF, minor allelic frequency) greater than 0.5% in databases such as Qianren, ESP6500, EXAC, etc., and filter out intergenic and intronic regions site, the mutation site that changes the a...

Embodiment 2

[0026] Application of Human Gene Panels Associated with Neoadjuvant Chemotherapy Drug Sensitivity:

[0027] A total of 102 cervical cancer samples were selected as the test group, and the entry conditions were as follows:

[0028] (1) Patients with cervical cancer receiving neoadjuvant chemotherapy;

[0029] (2) No other treatment was received before neoadjuvant chemotherapy;

[0030] (3) The pathological type is squamous cell carcinoma;

[0031] (4) FIGO stages IB1-IIB;

[0032] (5) Age 18-70 years old.

[0033] Taking the clinical manifestations of chemotherapy (sensitive or insensitive) as a reference, the clinical manifestations of chemotherapy are based on the curative effect evaluation criteria established by WHO, and the course of chemotherapy (1 to 2 courses, some sensitive patients can achieve good results with one chemotherapy, so only one chemotherapy ) after the end of the tumor elimination ratio greater than 50% is judged as chemotherapy sensitive, less than 5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology, and particularly relates to a human gene combination and application thereof to preparation of a kit for evaluating sensitivity of neoadjuvantchemotherapy drugs. The applicant performs whole exon sequencing (WES) analysis on DNA of a tissue sample of a cervical cancer patient with known neoadjuvant chemotherapy outcome, and performs variable screening on LOF mutation and missense mutation of the whole exon sequence of the sample with known chemotherapy outcome by using an LASSO regression analysis method, finally 15 genes are screened out to be related to the sensitivity of the cervical cancer neoadjuvant chemotherapy drugs, the kit for evaluating the sensitivity of the cervical cancer neoadjuvant chemotherapy drugs can be preparedby utilizing the combination of the 15 genes, the kit is high in prediction accuracy, the current clinical problem that the treatment effect needs to be judged according to the treatment result can beeffectively solved, and the kit is worthy of large-scale popularization.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to human gene combination and its application in the preparation and evaluation of neoadjuvant chemotherapy drug sensitivity kit. Background technique [0002] Neoadjuvant chemotherapy for cervical cancer is mainly used in the treatment of locally advanced cervical cancer. Its advantages are that it can reduce the tumor volume, facilitate the next treatment, and improve the sensitivity of radiotherapy. For early cervical cancer with a diameter ≥ 4 cm, neoadjuvant chemotherapy combined with radical surgery for cervical cancer is one of the standard options. [0003] Neoadjuvant chemotherapy in cervical cancer mainly adopts the chemotherapy regimen of cisplatin combined with paclitaxel. Neoadjuvant chemotherapy is a relatively effective treatment for cervical cancer, but about 20%-25% of patients are still insensitive to neoadjuvant chemotherapy. At present, there is no rel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/106C12Q2600/156Y02A50/30
Inventor 田训陈世民杨帆
Owner 武汉凯德维斯医学检验实验室有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com